On June 27, 2016, Genentech, a …
Read News ArticleCategory: Latest News
Eligible People with PPMS May Receive Experimental Medication
Ocrelizumab, an experimental m …
Read News ArticleMSAA Wins APEX 2016 Awards for Publication Excellence
MSAA has been awarded the APEX …
Read News ArticleThe Multiple Sclerosis Association of America Publishes New Resources
The Multiple Sclerosis Associa …
Read News ArticleMS Conversations Recognized as Top MS Blog of 2016 by Healthline.com
MSAA’s MS Conversations blog i …
Read News ArticleFDA Approves Zinbryta™ (Daclizumab) for Relapsing Forms of Multiple Sclerosis
Approval and Medication Overvi …
Read News ArticleMSAA Reopens MRI Access Fund
The Multiple Sclerosis Associa …
Read News ArticleWalking Awareness Survey Yields Interesting Results
During the 2016 March is MS Aw …
Read News ArticleIbudilast Receives Fast Track Designation from FDA
MediciNova, Inc., the biopharmaceutical company developing ibudilast (MN-166), announced that this investigational medication for progressive forms of MS has received Fast Track designation from the United States Food and Drug Administration (FDA). This designation is intended for drugs under development for treating serious diseases and with the potential to address unmet medical needs for such diseases.
Read News ArticleThe Multiple Sclerosis Association of America to Ring the Nasdaq Opening Bell
The Multiple Sclerosis Association of America (MSAA) is honored to ring the Nasdaq Stock Market Opening Bell on Friday, March 11, 2016 at Nasdaq MarketSite in recognition of Multiple Sclerosis Awareness Month. MSAA President & CEO Gina Ross Murdoch will ring the bell to open the market accompanied by members of the MS community.
Read News Article